495 related articles for article (PubMed ID: 27271250)
21. Treatment of metastatic renal cell carcinoma in older patients: A network meta-analysis.
Hale P; Hahn AW; Rathi N; Pal SK; Haaland B; Agarwal N
J Geriatr Oncol; 2019 Jan; 10(1):149-154. PubMed ID: 29861146
[TBL] [Abstract][Full Text] [Related]
22. First-line Systemic Therapy for Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis.
Wallis CJD; Klaassen Z; Bhindi B; Ye XY; Chandrasekar T; Farrell AM; Goldberg H; Boorjian SA; Leibovich B; Kulkarni GS; Shah PS; Bjarnason GA; Heng DYC; Satkunasivam R; Finelli A
Eur Urol; 2018 Sep; 74(3):309-321. PubMed ID: 29656851
[TBL] [Abstract][Full Text] [Related]
23. Axitinib, cabozantinib, or everolimus in the treatment of prior sunitinib-treated patients with metastatic renal cell carcinoma: results of matching-adjusted indirect comparison analyses.
Proskorovsky I; Benedict A; Negrier S; Bargo D; Sandin R; Ramaswamy K; Desai J; Cappelleri JC; Larkin J
BMC Cancer; 2018 Dec; 18(1):1271. PubMed ID: 30567533
[TBL] [Abstract][Full Text] [Related]
24. Targeted therapies for previously treated advanced or metastatic renal cell carcinoma: systematic review and network meta-analysis.
Karner C; Kew K; Wakefield V; Masento N; Edwards SJ
BMJ Open; 2019 Mar; 9(3):e024691. PubMed ID: 30826762
[TBL] [Abstract][Full Text] [Related]
25. Cabozantinib and nivolumab for renal cell carcinoma.
Worley L
Lancet Oncol; 2015 Nov; 16(15):e531. PubMed ID: 26481805
[No Abstract] [Full Text] [Related]
26. Cabozantinib: A Review in Advanced Renal Cell Carcinoma.
Al-Salama ZT; Keating GM
Drugs; 2016 Dec; 76(18):1771-1778. PubMed ID: 27909994
[TBL] [Abstract][Full Text] [Related]
27. Exposure-Response Analysis to Support Nivolumab Once Every 4 Weeks Dosing in Combination with Cabozantinib in Renal Cell Carcinoma.
Hamuro L; Hu Z; Passarell J; Barcomb H; Zhang J; Goldstein S; Bello A; Roy A; Zhu L
Clin Cancer Res; 2022 Apr; 28(8):1603-1613. PubMed ID: 34980597
[TBL] [Abstract][Full Text] [Related]
28. CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma.
Escudier B; Sharma P; McDermott DF; George S; Hammers HJ; Srinivas S; Tykodi SS; Sosman JA; Procopio G; Plimack ER; Castellano D; Gurney H; Donskov F; Peltola K; Wagstaff J; Gauler TC; Ueda T; Zhao H; Waxman IM; Motzer RJ;
Eur Urol; 2017 Dec; 72(6):962-971. PubMed ID: 28262413
[TBL] [Abstract][Full Text] [Related]
29. Network meta-analysis of second line and beyond treatment options in metastatic clear cell renal cell carcinoma.
Obeng-Kusi M; Kreutzfeldt JJ; Estrada-Mendizabal RJ; Choi BM; Abraham I; Recio-Boiles A
Urol Oncol; 2024 Feb; 42(2):32.e1-32.e8. PubMed ID: 38216444
[TBL] [Abstract][Full Text] [Related]
30. CheckMate for advanced-stage ccRCC? Nivolumab and cabozantinib aMETEORate poor survival.
Thoma C
Nat Rev Urol; 2015 Dec; 12(12):651. PubMed ID: 26458750
[No Abstract] [Full Text] [Related]
31. Cabozantinib for the treatment of patients with metastatic non-clear cell renal cell carcinoma: A retrospective analysis.
Campbell MT; Bilen MA; Shah AY; Lemke E; Jonasch E; Venkatesan AM; Altinmakas E; Duran C; Msaouel P; Tannir NM
Eur J Cancer; 2018 Nov; 104():188-194. PubMed ID: 30380460
[TBL] [Abstract][Full Text] [Related]
32. Kidney cancer: CheckMate for advanced-stage ccRCC? Nivolumab and cabozantinib aMETEORate poor survival.
Thoma C
Nat Rev Clin Oncol; 2015 Nov; 12(11):621. PubMed ID: 26462125
[No Abstract] [Full Text] [Related]
33. Real-World Treatment with Nivolumab or Cabozantinib for Metastatic Renal Cell Carcinoma (mRCC) in the Veneto Region of Italy: Results of AMOUR Study.
Maruzzo M; Pierantoni F; Bortolami A; Palleschi D; Zivi A; Nicodemo M; Sartori D; De Vivo R; Zustovich F; Bimbatti D; Pastorelli D; Vultaggio GD; Soraru' M; Ballestrin M; Modonesi C; Randisi P; Barile C; Perri G; Basso U; Zagonel V
Target Oncol; 2022 Jul; 17(4):467-474. PubMed ID: 35751733
[TBL] [Abstract][Full Text] [Related]
34. Cabozantinib, a New Standard of Care for Patients With Advanced Renal Cell Carcinoma and Bone Metastases? Subgroup Analysis of the METEOR Trial.
Escudier B; Powles T; Motzer RJ; Olencki T; Arén Frontera O; Oudard S; Rolland F; Tomczak P; Castellano D; Appleman LJ; Drabkin H; Vaena D; Milwee S; Youkstetter J; Lougheed JC; Bracarda S; Choueiri TK
J Clin Oncol; 2018 Mar; 36(8):765-772. PubMed ID: 29309249
[TBL] [Abstract][Full Text] [Related]
35. CaboPoint: a phase II study of cabozantinib as second-line treatment in patients with metastatic renal cell carcinoma.
Albiges L; Schmidinger M; Taguieva-Pioger N; Perol D; Grünwald V; Guemas E
Future Oncol; 2022 Mar; 18(8):915-926. PubMed ID: 34911359
[TBL] [Abstract][Full Text] [Related]
36. Real-world evidence of cabozantinib in patients with metastatic renal cell carcinoma: Results from the CABOREAL Early Access Program.
Albiges L; Fléchon A; Chevreau C; Topart D; Gravis G; Oudard S; Tourani JM; Geoffrois L; Meriaux E; Thiery-Vuillemin A; Barthélémy P; Ladoire S; Laguerre B; Perrot V; Billard A; Escudier B; Gross-Goupil M
Eur J Cancer; 2021 Jan; 142():102-111. PubMed ID: 33253997
[TBL] [Abstract][Full Text] [Related]
37. Long-term follow-up of overall survival for cabozantinib versus everolimus in advanced renal cell carcinoma.
Motzer RJ; Escudier B; Powles T; Scheffold C; Choueiri TK
Br J Cancer; 2018 May; 118(9):1176-1178. PubMed ID: 29576624
[TBL] [Abstract][Full Text] [Related]
38. Outcomes based on prior therapy in the phase 3 METEOR trial of cabozantinib versus everolimus in advanced renal cell carcinoma.
Powles T; Motzer RJ; Escudier B; Pal S; Kollmannsberger C; Pikiel J; Gurney H; Rha SY; Park SH; Geertsen PF; Gross-Goupil M; Grande E; Suarez C; Markby DW; Arroyo A; Dean M; Choueiri TK; George D
Br J Cancer; 2018 Sep; 119(6):663-669. PubMed ID: 30197417
[TBL] [Abstract][Full Text] [Related]
39. An Illustrative Case of Combination Cabozantinib/Nivolumab for Progressive Metastatic Renal Cell Carcinoma (mRCC).
Kao C; George DJ; Zhang T
Oncologist; 2021 Mar; 26(3):e508-e511. PubMed ID: 33251710
[TBL] [Abstract][Full Text] [Related]
40. Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: the Italian expanded access program.
Verzoni E; Cartenì G; Cortesi E; Giannarelli D; De Giglio A; Sabbatini R; Buti S; Rossetti S; Cognetti F; Rastelli F; Sobrero A; Turci D; Sternberg CN; Porta C; Cappuzzo F; Tortora G; Tassinari D; Panni S; Pazzola A; Surico G; Raimondi A; De Giorgi U; Procopio G;
J Immunother Cancer; 2019 Apr; 7(1):99. PubMed ID: 30944023
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]